1. Treier M, Gleiberman AS, O’Connell
SM, et al. Multistep signaling requirements for pituitary organogenesis
in vivo. Genes Dev. 2000;12:1691-1704.
2. Mullis PE. Genetic control of growth. Eur J Endocrinol. 2005;152(1):11-31.
3. Rosenfeld MG, Briata P, Dasen J, et al. Multistep signaling
and transcriptional requirements for pituitary organogenesis.
Recent
Prog Horm Res. 2000;55:1-13.
[PubMed: 11036930]
4. Moore GE, Abu-Amero S, Wakeling E, et al. The search for
the gene for Silver-Russell syndrome. Acta Paediatr Suppl. 1999;433:42-48.
5. Sheng HZ, Westphal H. Early steps in pituitary organogenesis. Trends
Genet. 1999;15(6):236-240.
6. Ericson J, Norlin S, Jessell TM, Edlund T. Integrated FGF
and BMP signaling controls the progression of progenitor cell differentiation
and the emergence of pattern in the embryonic anterior pituitary. Development. 1999;125:1005-1015.
7. Thorner MO, Vance ML, Horvath E, Kovacs K. The anterior pituitary.
In: Wilson JD, Foster DW, eds. Williams Textbook of Endocrinology.
8th ed. Philadelphia: WB Saunders; 1991: 210-221.
8. Scheithauer BW, Sano T, Kovacs K, Young WF, Ryan N, Randall
RV. The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical
study of 69 cases.
Mayo Clin Proc. 1990;65:461-474.
[PubMed: 2159093]
9. Hoyt WF, Kaplan SL, Grumbach MM, Glaser JS. Septo-optic dysplasia
and pituitary dwarfism.
Lancet. 1970;1:893-894.
[PubMed: 4191531]
10. Pavel ME, Hensen J, Pfaffle R, Hahn EG, Dorr HG. Long-term
follow-up of childhood-onset hypopituitarism in patients with the
PROP-1 gene mutation. Horm Res. 2003;60(4):168-173.
11. Stewart PW. The adrenal cortex. In: Kronenberg HM, Melmed
S, Polonsky KS, Larsen PR, eds. Williams Textbook of Endocrinology.
11th ed. Philadelphia: Saunders-Elsevier; 2008: 445-504.
12. Frankenne F, Closset J, Gomez F, Scippo ML, Smal J, Hennen
G. The physiology of growth hormones (GHs) in pregnant women and
partial characterization of the placental GH variant.
J
Clin Endocrinol Metab. 1988;66:1171-1180.
[PubMed: 3372680]
13. Cooke NE, Ray J, Watson MA, Estes PA, Kuo BA, Liebhaber
SA. Human growth hormone gene and the highly homologous growth hormone
variant gene display different splicing patterns.
J Clin
Invest. 1988;82:270-275.
[PubMed: 3392209]
14. Reiter EO, Rosenfeld RG. Normal and aberrant growth. In:
Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Williams
Textbook of Endocrinology. 11th ed. Philadelphia: Saunders-Elsevier;
2008: 849-968.
15. Kaplan SA, Cohen P. The somatomedin hypothesis 2007: 50
years later. J Clin Endocrinol Metab. 2007;92(12):4529-4535.
16. Furlanetto RW, DiCarlo JN, Wisehart C. The type II insulin-like
growth factor receptor does not mediate deoxyribonucleic acid synthesis
in human fibroblasts.
J Clin Endocrinol Metab. 1987;64:1142-1149.
[PubMed: 2952664]
17. Mottola C, Czech MP. The type II insulin-like growth factor
receptor does not mediate DNA synthesis in H-35 hepatoma cells.
J
Biol Chem. 1984;259:12705-12713.
[PubMed: 6092344]
18. Kiess W, Haskell JF, Lee L, et al. An antibody that blocks
insulin-like growth factor (IGF) binding to the type II IGF receptor
is neither an agonist nor an inhibitor of IGF-stimulated biologic
response in L6 myoblasts. J Biol Chem. 1987;162:12756-12761.
19. Adashi EY, Resnick CE, Rosenfeld RG. Insulin-like growth
factor-I (IGF-I) hormonal action in cultured rat granulosa cells:
mediation via type I but not type II IGF receptors. Endocrinology. 1989;126:216-222.
20. Kaplan SA, Cohen P. The somatomedin hypothesis 2007: 50
years later. J Clin Endocrinol Metab. 2007;92(12):4529-4535.
21. Rechler MM. Insulin-like growth factor binding proteins.
Vitam
Horm. 1993;47:1-114.
[PubMed: 7680510]
22. Jones JI, Clemmons DR. Insulin-like growth factors and their
binding proteins: biological actions.
Endocr Rev. 1995;16:3-34.
[PubMed: 7758431]
23. Oh Y, Muller HL, Lee DY, Fielder PJ, Rosenfeld RG. Characterization
of the affinities of insulin-like growth factor (IGF)-binding proteins
1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I
analogs.
Endocrinology. 1993;132:1337-1344.
[PubMed: 7679979]
24. Leong SR, Baxter RC, Camerato T, Dai J, Wood WI. Structure
and functional expression of acid labile subunit of the insulin-like
growth factor binding protein complex.
Mol Endocrinol.
1992;6:870-876.
[PubMed: 1379671]
25. Baxter RC, Martin JL. Structure of the Mr 140,000 growth
hormone-dependent insulin-like growth factor binding protein complex:
demonstration by reconstitution and affinity labeling.
Proc
Natl Acad Sci USA. 1989;86:6898-6902.
[PubMed: 2476804]
26. Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth
factors I and II in health man. Estimations of half-lives and production
rates.
Acta Endocrinol. 1989;121:753-758.
[PubMed: 2558477]
27. De Mellow JSM, Baxter RC. Growth hormone-dependent insulin-like
growth factor (IGF) binding protein both inhibits and potentiates
IGF-I-stimulated DNA synthesis in human skin fibroblasts. Biochem
Biophys Res Commun. 1988;156:199-204.
28. Conover CA, Ronk M, Lombana F, Powell DR. Structural and
biological characterization of bovine insulin-like growth factor
binding protein-3.
Endocrinology. 1990;127:2795-2803.
[PubMed: 1701128]
29. Oh Y, Muller HL, Ng L, Rosenfeld RG. Transforming growth
factor-beta-induced cell growth inhibition in human breast cancer
cells is mediated through insulin-like growth factor binding protein-3
action.
J Biol Chem. 1995;270:13589-13592.
[PubMed: 7539790]
30. Conover CA, Bale LK, Durham SK, Powell DR. Insulin-like
growth factor (IGF) binding protein-3 potentiation of IGF action
is mediated through the phosphatidylinositol-3-kinase pathway and
is associated with alteration in protein kinase B/AKT sensitivity.
Endocrinology. 2000;141:3098-3103.
[PubMed: 10965879]
31. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor
(IGF) binding protein-3 induces apoptosis and mediates the effects
of transforming growth factor-beta on programmed cell death through
a p53- and IGF-independent mechanism. J Biol Chem.
2000;275:33607-33613.
32. Bilezikian J, Morishima A, Bell J, Grumbach MM. Increased
bone mass as a result of estrogen therapy in a man with aromatase
deficiency. N Engl J Med. 1998;339(9):599-603.
33. Gluckman PD, Barrett-Johnson JJ, Butler JH, Edgar BW, Gunn
TR. Studies of insulin-like growth factor I and II by specific radioligand
assays in umbilical cord blood.
Clin Endocrinol.
1983;19:405-413.
[PubMed: 6354521]
34. Luna AM, Wilson DM, Wibbelsman CJ, et al. Somatomedins in
adolescence: a cross-sectional study of the effect of puberty on
plasma insulin-like growth factor I and II levels. J Clin
Endocrinol Metab. 1983;57:258-271.
35. Cara JF, Rosenfield RL, Furlanetto RW. A longitudinal study
of the relationship of plasma somatomedin-C concentration to the
pubertal growth spurt.
Am J Dis Child. 1987;141:562-564.
[PubMed: 3578171]
36. Rudman D, Feller AG, Nagraj HS, et al. Effects of human
growth hormone in men over 60 years old.
N Engl J Med. 1990;323:1-6.
[PubMed: 2355952]
37. Johanson AJ, Blizzard RM. Low somatomedin-C levels in older
men rise in response to growth hormone administration.
Johns
Hopkins Med J. 1981;149:115-117.
[PubMed: 7197311]
38. Donovan SM, Oh Y, Pham H, Rosenfeld RG. Ontogeny of serum
insulin-like growth factor binding proteins in the rat.
Endocrinology. 1989;125:2621-2627.
[PubMed: 2477234]
39. Hartman ML, Veldhuis JD, Thorner MO. Normal control of growth
hormone secretion.
Horm Res. 1993;40:37-47.
[PubMed: 8300049]
40. Veldhuis JD, Liem AY, South S, et al. Differential impact
of age, sex steroid hormones, and obesity on basal versus pulsatile
growth hormone secretion in men as assessed in an ultrasensitive
chemiluminescence assay.
J Clin Endocrinol Metab. 1995;80:3209-3222.
[PubMed: 7593428]
41. Martha PM Jr, Reiter EO. Pubertal growth and growth hormone
secretion.
Endocrinol Metab Clin North Am. 1991;20:165-182.
[PubMed: 2029886]
42. Veldhuis JD, Johnson ML. Deconvolution analysis of hormone
data.
Methods Enzymol. 1992;210:539-575.
[PubMed: 1584051]
43. Gill MS, Thalange NK, Foster PJ, et al. Regular fluctuations
in growth hormone (GH) release determine normal human growth. Growth
Horm IGF Res. 1999;9(2):114-122.
44. Tillmann V, Gill MS, Thalange NK, et al. Short-term changes
in growth and urinary growth hormone, insulin-like growth factor-I
and markers of bone turnover excretion in healthy prepubertal children. Growth
Horm IGF Res. 2000;10(1):28-36.
45. Van Cauter E, Caufriez A, Kerkhofs M, Van Onderbergen A,
Thorner MO, Copinschi G. Sleep, awakenings, and insulin-like growth
factor-I modulate the growth hormone (GH) secretory response to
GH-releasing hormone. J Clin Endocrinol Metab. 1992;74(6):1451-1459.
46. Schalch DS. The influence of physical stress and exercise
on growth hormone and insulin secretion in man.
J Lab Clin
Med. 1967;69:256.
[PubMed: 6016624]
47. Ceda GP, Davis RG, Rosenfeld RG, Hoffman AR. The growth
hormone (GH) releasing hormone (GHRH)-GH-somatomedin axis: evidence
for rapid inhibition of GHRH-elicited GH release by insulin-like
growth factors I and II.
Endocrinology. 1987;120:1658-1662.
[PubMed: 3104015]
48. Korbonits M, Grossman AB. Growth hormone-releasing peptide
and its analogues.
Trends Endocrinol Metab. 1995;6:43-49.
[PubMed: 18406682]
49. Smith RG, Palyha OC, Feighner SD, et al. Growth hormone
releasing substances: types and their receptors. Horm Res. 1999;51(suppl
3):1-8.
50. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa
K. Ghrelin is a growth-hormone-releasing acylated peptide from the
stomach.
Nature. 1999;402:656-660.
[PubMed: 10604470]
51. Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth
hormone-releasing acylated peptide, is synthesized in a distinct
endocrine cell type in the gastrointestinal tract of rats and humans. Endocrinology. 2000;141(11):4255-4261.
52. Wren AM, Small CJ, Ward HL, et al. The novel peptide ghrelin
stimulates food intake and growth hormone secretion. Endocrinology. 2000;141(11):4325-4328.